Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH

J. Gregory Cairncross, Meihua Wang, Robert Brian Jenkins, Edward G. Shaw, Caterina Giannini, David G. Brachman, Jan Craig Buckner, Karen L. Fink, Luis Souhami, Normand J. Laperriere, Jason T. Huse, Minesh P. Mehta, Walter J. Curran

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

Purpose: Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. Patients and Methods: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. Results: IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. Conclusion: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.

Original languageEnglish (US)
Pages (from-to)783-790
Number of pages8
JournalJournal of Clinical Oncology
Volume32
Issue number8
DOIs
StatePublished - Mar 10 2014

Fingerprint

Lomustine
Procarbazine
Vincristine
Chemoradiotherapy
Mutation
Radiotherapy
Neoplasms
Radiation Oncology
Survival
Germ-Line Mutation
Alkylating Agents
Glioma
Disease-Free Survival
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH. / Cairncross, J. Gregory; Wang, Meihua; Jenkins, Robert Brian; Shaw, Edward G.; Giannini, Caterina; Brachman, David G.; Buckner, Jan Craig; Fink, Karen L.; Souhami, Luis; Laperriere, Normand J.; Huse, Jason T.; Mehta, Minesh P.; Curran, Walter J.

In: Journal of Clinical Oncology, Vol. 32, No. 8, 10.03.2014, p. 783-790.

Research output: Contribution to journalArticle

Cairncross, JG, Wang, M, Jenkins, RB, Shaw, EG, Giannini, C, Brachman, DG, Buckner, JC, Fink, KL, Souhami, L, Laperriere, NJ, Huse, JT, Mehta, MP & Curran, WJ 2014, 'Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH', Journal of Clinical Oncology, vol. 32, no. 8, pp. 783-790. https://doi.org/10.1200/JCO.2013.49.3726
Cairncross, J. Gregory ; Wang, Meihua ; Jenkins, Robert Brian ; Shaw, Edward G. ; Giannini, Caterina ; Brachman, David G. ; Buckner, Jan Craig ; Fink, Karen L. ; Souhami, Luis ; Laperriere, Normand J. ; Huse, Jason T. ; Mehta, Minesh P. ; Curran, Walter J. / Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 8. pp. 783-790.
@article{d7e5204b861149caa94b1d0825ed28c2,
title = "Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH",
abstract = "Purpose: Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. Patients and Methods: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. Results: IDH status was evaluable in 210 of 291 patients; 156 (74{\%}) had mutations. rs55705857 was evaluable in 245 patients; 76 (31{\%}) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95{\%} CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95{\%} CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6{\%} v RT, 4{\%}). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95{\%} CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95{\%} CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. Conclusion: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.",
author = "Cairncross, {J. Gregory} and Meihua Wang and Jenkins, {Robert Brian} and Shaw, {Edward G.} and Caterina Giannini and Brachman, {David G.} and Buckner, {Jan Craig} and Fink, {Karen L.} and Luis Souhami and Laperriere, {Normand J.} and Huse, {Jason T.} and Mehta, {Minesh P.} and Curran, {Walter J.}",
year = "2014",
month = "3",
day = "10",
doi = "10.1200/JCO.2013.49.3726",
language = "English (US)",
volume = "32",
pages = "783--790",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH

AU - Cairncross, J. Gregory

AU - Wang, Meihua

AU - Jenkins, Robert Brian

AU - Shaw, Edward G.

AU - Giannini, Caterina

AU - Brachman, David G.

AU - Buckner, Jan Craig

AU - Fink, Karen L.

AU - Souhami, Luis

AU - Laperriere, Normand J.

AU - Huse, Jason T.

AU - Mehta, Minesh P.

AU - Curran, Walter J.

PY - 2014/3/10

Y1 - 2014/3/10

N2 - Purpose: Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. Patients and Methods: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. Results: IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. Conclusion: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.

AB - Purpose: Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. Patients and Methods: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. Results: IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. Conclusion: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.

UR - http://www.scopus.com/inward/record.url?scp=84899760157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899760157&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.49.3726

DO - 10.1200/JCO.2013.49.3726

M3 - Article

C2 - 24516018

AN - SCOPUS:84899760157

VL - 32

SP - 783

EP - 790

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -